(FILE 'HOME' ENTERED AT 15:52:35 ON 07 DEC 96)

FILE 'REGISTRY' ENTERED AT 15:52:42 ON 07 DEC 96

	FILE KEGI	SIKI	EMIEL	CED AI	13.32.42	OIN	0 /	DEC	90
L1		STRUC	CTURE	UPLOAI	DED				
L2		STRUC	CTURE	UPLOAI	DED				
L3		STRUC	CTURE	UPLOAI	DED				
L4	0	S L1							
L5	0	S L1	FULL						
L6	0	S L2	FULL						
L7	0	S L3	FULL						

structure rearch of compounds in claim 3

=> d his

(FILE 'USPAT' ENTERED AT 15:58:20 ON 07 DEC 96)

L1 145 S (ISOCYANATE# OR POLYISOCYANATE# OR DIISOCYANATE#) (P) (AMI NE#

=> d 4,8,10

4. 5,516,935, May 14, 1996, Process for the production of diisocyanates; Eric Bischof, et al., 560/347 [IMAGE AVAILABLE]

8. 5,449,818, Sep. 12, 1995, Process for the preparation of aromatic diisocyanates; Klaus Biskup, et al., 560/347 [IMAGE AVAILABLE]

10. 5,391,683, Feb. 21, 1995, Preparation of aromatic polyisocyanates; Faouzi Joulak, et al., 528/67; 560/338, 347 [IMAGE AVAILABLE]

The bis(2-isocyanatoethyl)ether is a known compound and can be prepared by reacting **phosgene** with bis(2-**aminoethyl**)**ether** or the chlorobenzene) at elevated temperatures.

BROW(13)

:YAAMMUS

US PAT NO: 5,516,935 [IMAGE AVAILABLE] L1: 4 of 145

ABSTRACT:

Diisocyanates are produced by gas-phase phosgenation of aliphatic diamines having two primary amino groups in the 1,2- or 1,3-position to one another or by cycloaliphatic diamines having two primary amino groups in the 1,2- or 1,3-position to one another.

US PAT NO: 5,449,818 [IMAGE AVAILABLE] L1: 8 of 145

ABSTRACT:

A continuous process for the preparation of aromatic diisocyanates by phosgenation of the corresponding diamines, in which the reaction is carried out in the gas phase. The mean contact time for the gaseous reactants is from 0.5 to 5 seconds with a mean deviation of no more than 6%. The product diisocyanate is obtained in yields of over 95%.

US PAT NO: 5,391,683 [IMAGE AVAILABLE] L1: 10 of 145

ABSTRACT:

Aromatic **polyisocyanates**, e.g., toluene **diisocyanate**, are prepared by reacting/contacting at least one aromatic compound (A) bearing at least two primary **amine** substituents, e.g., toluenediamine, xylylenediamine and/or phenylenediamine,, with **phosgene**, in **gaseous** phase and in a reactor/reaction zone devoid of active mechanical stirring.

=> d 1-10

PA

L9 ANSWER 1 OF 10 USPATFULL

AN 96:94579 USPATFULL

Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a receptor

Blackburn, Brent, San Francisco, CA, United States
Barker, Peter, El Granada, CA, United States
Gadek, Thomas, Oakland, CA, United States
McDowell, Robert, San Francisco, CA, United States
McGee, Lawrence, Pacifica, CA, United States
Somers, Todd, Montara, CA, United States
Webb, Rob, Moss Beach, CA, United States

LYAMINEETHER# OR AMINEETHER#)

Robarge, Kirk, San Francisco, CA, United States
Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

PI US 5565449 961015

AI US 95-452479 950526 (8)

Division of Ser. No. US 93-70457, filed on 8 Jun 1993 which is a continuation in-part of Ser. No. US 92-866931, filed on 10 Apr 1992, now patented, Pat. No. US 5250679 which is a continuation-in-part of Ser. No. US 91-781477, filed on 18 Oct 1991, now abandoned

DT Utility LN.CNT 13455

INCL INCLM: 514/219.000

NCL NCLM: 514/219.000

NCLS: 514/220.000; 514/221.000; 540/493.000; 540/495.000; 540/504.000; 540/512.000

IC [6]

ICM: A61K031-55

EXF 540/493; 540/495; 540/504; 540/512; 514/219; 514/220; 514/221 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 10 USPATFULL

AN 95:29638 USPATFULL

TI Benzazepine platelet aggregation inhibitors having specificity for the GPII.sub.b III.sub.a receptor

'Blackburn, Brent, San Francisco, CA, United States INMcDowell, Robert, San Francisco, CA, United States Gadek, Thomas, Oakland, CA, United States Webb, Rob, Moss Beach, CA, United States Genentech, Inc., So. San Francisco, CA, United States (U.S. PAcorporation) US 5403836 950404 PΙ US 93-58722 930506 (8) AΙ Division of Ser. No. US 92-866931, filed on 10 Apr 1992, now RLI patented, Pat. No. US 5250679 which is a continuation-in-part of Ser. No. US 91-781477, filed on 18 Oct 1991, now abandoned Utility DT LN.CNT 11322 INCLM: 514/213.000 INCL INCLS: 540/495.000; 540/506.000; 540/523.000 NCLM: 514/213.000 NCL NCLS: 540/495.000; 540/506.000; 540/523.000 ΙC [6] ICM: A61K031-55 ICS: C07D223-16 540/523; 514/213 EXF CAS INDEXING IS AVAILABLE FOR THIS PATENT. L9 ANSWER 3 OF 10 USPATFULL AN93:82994 USPATFULL TΙ Nonpeptidyl platelet aggregation inhibitors having specificity for the GPII.sub.b III.sub. receptor Blackburn, Brent, San Francisco, CA, United States ΙN McDowell, Robert, San Francisco, CA, United States Gadek, Thomas, Oakland, CA, United States Barker, Peter, El Granada, CA, United States McGee, Lawrence, Pacifica, CA, United States Webb, Rob, Moss Beach, CA, United States Genentech, Inc., South San Francisco, CA, United States (U.S. PΑ corporation) US 5250679 931005 PΙ US 92-866931 920410 (7) ΑI RLI Continuation-in-part of Ser. No. US 91-781477, filed on 18 Oct 1991, now abandoned Utility DTLN.CNT 10784 INCL INCLM: 540/490.000 INCLS: 540/495.000; 540/512.000; 540/523.000 NCLM: 540/490.000 NCL NCLS: 540/495.000; 540/512.000; 540/523.000 IC [5] ICM: C07D261-14 ICS: A61K031-55 540/506; 540/490 EXF CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
ANSWER 4 OF 10 USPATFULL
L9
       91:68540 USPATFULL
AN
       Polyether substituted mannich bases and lubricant ashless
TΙ
       dispersants
      Blain, David A., Mt. Laurel, NJ, United States
ΙN
       Cardis, Angeline B., Florence, NJ, United States
      Mobil Oil Corp., Fairfax, VA, United States (U.S. corporation)
PΑ
      US 5043086 910827
PΙ
      US 90-549047 900706 (7)
ΑI
      Continuation-in-part of Ser. No. US 88-280457, filed on 6 Dec 1988
RLI
      Utility
DT
LN.CNT 358
     INCLM: 252/051.500R
INCL
      NCLM: 508/558.000
NCL
      NCLS: 508/561.000
      [5]
ΙC
       ICM: C10M133-06
EXF
      252/51.5R
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 5 OF 10 USPATFULL
L9
       91:64470 USPATFULL
AN
       Polyether substituted mannich bases as fuel and lubricant ashless
ΤI
      dispersants
      Blain, David A., Morrisville, PA, United States
ΙN
       Cardis, Angeline B., Florence, NJ, United States
      Mobil Oil Corporation, New York, NY, United States (U.S.
PA
       corporation)
      US 5039310 910813
PΙ
ΑI
      US 88-280457 881206 (7)
      Utility
DT
LN.CNT 401
      INCLM: 044/424.000
INCL
       INCLS: 044/425.000; 564/367.000; 564/370.000; 564/390.000
      NCLM: 044/424.000
NCL
      NCLS: 044/425.000; 564/367.000; 564/370.000; 564/390.000
IC
      [5]
       ICM: C10L001-22
       ICS: C07C211-00; C07C215-00
       252/50; 252/51.5A; 252/351; 252/355; 252/357; 044/72; 044/424;
EXF
       044/425; 564/367; 564/370; 564/390
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 6 OF 10 USPATFULL
L9
       35:63880 USPATFULL
AN
       1-Sulfo-2-oxoazetidine derivatives and their production
ΤI
      Matsuo, Taisuke, Ibaraki, Japan
ΙN
       Kishimoto, Shoji, Takarazuka, Japan
       Ochiai, Michihiko, Suita, Japan
       Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S.
PΑ
       corporation)
```

```
·US 4550105 851029
PΙ
ΑI
       US 81-326937 811203 (6)
PRAI
      WO 80-JP297 801205
       WO 81-JP103 810430
       WO 81-JP183 810821
       WO 81-JP252
                   810924
DT
       Utility
LN.CNT 18339
      INCLM: 514/210.000
INCL
       INCLS: 544/359.000; 544/360.000; 260/239.000A; 544/362.000;
              544/363.000; 260/245.400; 544/364.000; 544/365.000;
              260/330.300; 544/366.000; 544/367.000; 260/330.900;
              544/369.000; 544/370.000; 544/090.000; 544/371.000;
              544/372.000; 544/238.000; 544/374.000; 544/377.000;
              544/229.000; 544/379.000; 544/405.000; 544/279.000;
              544/406.000; 544/407.000; 544/295.000; 544/408.000;
              544/409.000; 544/296.000; 546/014.000; 546/114.000;
              544/298.000; 546/122.000; 546/123.000; 544/300.000;
              546/153.000; 546/155.000; 544/301.000; 546/156.000;
              546/157.000; 544/310.000; 546/159.000; 546/162.000;
              544/311.000; 546/187.000; 546/193.000; 544/316.000;
              546/194.000; 546/197.000; 544/317.000; 546/208.000;
              546/209.000; 544/319.000; 546/210.000; 546/211.000;
              544/320.000; 546/256.000; 546/261.000; 544/321.000;
              546/263.000; 546/264.000; 544/322.000; 546/270.000;
              546/275.000; 544/323.000; 546/276.000; 546/277.000;
              544/324.000; 546/278.000; 546/279.000; 544/325.000;
              546/280.000; 546/281.000; 544/327.000; 544/331.000;
              544/332.000; 544/333.000; 544/334.000; 544/335.000;
              544/336.000; 544/357.000
             514/210.000
NCL
       NCLM:
              540/355.000; 544/090.000; 544/229.000; 544/279.000;
       NCLS:
              544/296.000; 544/310.000; 544/316.000; 544/319.000;
              544/321.000; 544/324.000; 544/328.000; 544/331.000
IC
       [4]
       ICM: C07D205-08
       ICS: C07D403-12; C07D401-12; A61K031-395
EXF
       260/239A; 260/245.4; 260/330.3; 260/330.9; 544/229; 544/238;
       544/279; 544/295; 544/296; 544/298; 544/300; 544/301; 544/310;
       544/311; 544/316; 544/317; 544/319-325; 544/327; 544/331-336;
       544/357; 544/359; 544/360; 544/362-367; 544/369-372; 544/374;
       544/377; 544/379; 544/405-409; 546/14; 546/114; 546/122; 546/123;
       546/153: 546/155-157: 546/159; 546/162; 546/187; 546/193; 546/194;
       546/197; 546/208-211; 546/256; 546/261; 546/263; 546/264; 546/270;
       546/275-281; 514/210
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
     ANSWER 7 OF 10 USPATFULL
      85:47656 USPATFULL
ΑN
      Method of forming polymeric layers
TI
IN
      Axen, Rolf E., Balinge, Sweden
```

```
. · Kai, Goran L., Uppsala, Sweden
       Rigner, Bror S., Uppsala, Sweden
      Pharmacia AB, Uppsala, Sweden (non-U.S. corporation)
PA
      US 4535010 850813
FI
      US 83-542507 831017 (6)
AΙ
PRAI SE 82-5908 821018
DT
   Utility
LN.CNT 960
      INCLM: 427/246.000
INCL
      INCLS: 427/245.000; 210/490.000; 210/500.200
      NCLM: 427/246.000
NCL
      NCLS: 210/490.000; 210/500.270; 210/500.420; 427/245.000
ΙC
      [3]
      ICM: B05D005-00
      427/246; 427/245; 210/490; 210/500.2
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 8 OF 10 USPATFULL
L9
AN
       84:3113 USPATFULL
      Liquid crystal material containing disazo dyestuffs
TI
      Claussen, Uwe, Leverkusen, Germany, Federal Republic of
ΙN
     Bayer Aktiengesellschaft, Leverkusen, Germany, Federal Republic of
PA
      (non-U.S. corporation)
      US 4426312 840117
PΙ
     US 81-330631 811214 (6)
ΑI
PRAI DE 80-3049454 801230
DT
      Utility
LN.CNT 260
INCL INCLM: 252/299.100
      INCLS: 350/349.000
NCL
     NCLM: 252/299.100
ΙC
      [3]
       ICM: C09K003-34
      ICS: G02F001-13
       252/299.1; 350/349
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
    ANSWER 9 OF 10 USPATFULL
L9
       83:11972 USPATFULL
AN
      Herbicidal N-[4-(3'-alkoxyphenoxy)-phenyl]-N'-methylureas
ΤI
      Rohr, Otto, Therwil, Switzerland
ΙN
       Pissiotas, Georg, Lorrach, Germany, Federal Republic of
      Ciba-Geigy Corporation, Ardsley, NY, United States (U.S.
PΑ
      corporation)
      US 4376646 830315
PI
      US 81-241295 810306 (6)
ΑI
      CH 80-2123 300318
PRAI
      CH 80-2124 800318
DT
      Utility
LN.CNT 702
INCL
      INCLM: 071/120.000
```

```
.-INCLS: 071/088.000; 071/090.000; 071/092.000; 071/094.000;
              071/095.000; 071/098.000; 071/103.000; 071/105.000;
              071/106.000; 260/453.000RW; 260/456.000A; 260/465.000D;
              560/251.000; 564/049.000; 564/051.000; 564/052.000
              504/332.000
NCL
       NCLM:
       NCLS: 504/166.000; 504/167.000; 504/168.000; 504/171.000;
              504/172.000; 504/173.000; 504/221.000; 504/224.000;
              504/225.000; 504/226.000; 504/235.000; 504/248.000;
              504/249.000; 504/283.000; 504/287.000; 504/304.000;
              504/305.000; 504/310.000; 504/311.000; 504/312.000;
              504/315.000; 504/319.000; 504/331.000; 558/058.000;
              558/389.000; 558/413.000; 558/417.000; 560/251.000;
              560/313.000; 564/049.000; 564/051.000; 564/052.000
ΙC
       [3]
       ICM: A01N009-20
       ICS: C07C127-19
       564/49; 564/51; 564/52; 071/120; 260/465D; 260/456A; 260/453RW;
EXF
       560/251
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9
     ANSWER 10 OF 10 USPATFULL
       76:70607 USPATFULL
AN
       1,1,3-Trisubstituted hydroxyguanidines
TI
       Cherkofsky, Saul Carl, Wilmington, DE, United States
ΙN
       E. I. Du Pont de Nemours and Company, Wilmington, DE, United
PΑ
       States (U.S. corporation)
PΙ
       US 4000196 761228
       US 74-533652 741217 (5)
ΑI
       Continuation-in-part of Ser. No. US 73-373147, filed on 25 Jun
RLI
       1973, now patented, Pat. No. US 3867447
DT
       Utility
LN.CNT 281
       INCLM: 260/565.000
INCL
       INCLS: 260/556.000AR; 260/556.000B; 260/556.000S; 260/558.000S;
              260/397.700R; 260/558.000A; 260/559.000T; 260/559.000S;
              260/559.000A
       NCLM: 564/229.000
NCL
       NCLS: 564/086.000; 564/238.000
       [2]
ΙC
       ICM: C07C133-10
       260/564G; 260/564A; 260/565; 260/556AR; 260/556B; 260/556S;
EXF
       260/558S; 260/558A; 260/559T; 260/559S; 260/559A; 260/397.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```